Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences' SensiDerm Assays Prioritized by Cosmetics Europe for Further Development


Proteome Sciences said this week that its SensiDerm multiplex protein assays for detection of sensitizers and allergens in cosmetics have been prioritized for further development by Cosmetics Europe, the European trade organization for the cosmetics, toiletry, and perfumery industry.

The assays, which comprise tests for more than 200 patented skin and respiratory markers, emerged from the company's participation in the EU-funded Sens-it-iv project, a research initiative aimed at developing in vitro testing methods that could replace animal testing for cosmetic sensitization studies.

As of March 13, 2013, a ban went into effect in the EU on animal testing of cosmetics ingredients.

Proteome Sciences identified the markers using its mass spec-based proteomic biomarker discovery platform and has developed assays to them using its Tandem Mass Tagging technology combined with selected-reaction monitoring mass spec.

Cosmetics Europe's decision to prioritize the assays means that the company is eligible to receive funding from that organization and the EU for "further development, optimization, and standardization" of the tests, Proteome Sciences said, although it added that details have yet to be agreed upon.

“We look forward to working with Cosmetics Europe to develop our SensiDerm multiplex tests commercially that are rapid, easy to use, and highly sensitive that will provide the means for companies to meet the EU requirement for non-animal testing for sensitizers in their products and in particular dermatological and respiratory allergens," CEO Christopher Pearce said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.